China Botanic Pharmaceutical Inc. Announces Receipt of Warning
Letter
HARBIN, China, Jan. 15, 2013 /PRNewswire/ -- China Botanic
Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals,
Inc.) ("China Botanic" or the "Company"), a developer, manufacturer
and distributor of botanical products, bio-pharmaceuticals and
traditional Chinese medicines ("TCM") in China, announced today that it received a
warning letter from the NYSE MKT LLC ("NYSE MKT") that the
Company is not in compliance with Section 803(B)(2)(a)(iii) of
the NYSE MKT LLC Company Guide (the "Company Guide"), in that it
has failed to maintain at least one member of the Audit Committee
who is financially sophisticated. Such non-compliance is a
result of the previously announced resignation of Zack Pan from the Company's board of
directors, audit chair and committees thereof. The Company has
until the earlier of its next annual shareholders' meeting or
January 11, 2014, whichever comes
first or if the next annual meeting is held before March 25, 2013, by March
25, 2013 to regain compliance with the Section
803(B)(2)(a)(iii) of the Company Guide. The Company is continuing
its efforts to search for a replacement director who is financially
sophisticated and expects that it will appoint a replacement
director within the foregoing time period and therefore regain
compliance with the applicable listing standards.
ABOUT CHINA BOTANIC
PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research,
development, manufacturing, and distribution of botanical products,
bio-pharmaceutical products, and traditional Chinese medicines
("TCM"), in the People's Republic of
China. All of the Company's products are produced at its
three GMP-certified production facilities in Ah City, Dongfanghong
and Qingyang. The Company distributes its botanical anti-depression
and nerve-regulation products, biopharmaceutical products, and
botanical antibiotic and OTC TCMs through its network of over 3,000
distributors and over 70 sales centers across 24 provinces in
China. For more information,
please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may
include forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are based upon management's beliefs, assumptions and expectations
of the Company's future operations and financial performance,
taking into account the information currently available to
management. These statements are not statements of historical fact.
Forward-looking statements involve risks and uncertainties, some of
which are not currently known that may cause actual results,
performance or financial condition to be materially different from
the expectations of future results, performance or financial
condition expressed or implied in any forward-looking statements.
These forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties
including, but not limited to, the Company's ability to manage
expansion of its operations effectively, and other factors detailed
in the Company's annual report on Form 10-K and other filings with
the Securities and Exchange Commission. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented herein.
Company
Contact:
|
China Botanic
Pharmaceutical Inc.
|
Ms. Portia Tan, IR
Contact
|
Tel:
86-451-8260-2162
|
Email:
ir@renhuang.com
|
SOURCE China Botanic Pharmaceutical Inc.